Laryngeal airway devices for human and veterinary use include an airway tube having a distal end and a proximal end. The distal end of the airway tube is provided with a pre-formed and non-inflatable peri-pharyngeal bowl. The peri-pharyngeal bowl has a posterior bowl portion having a back dorsal portion and a side wall extending around and depending from the periphery of the back dorsal portion to define an internal space, and further having a resiliently deformable flange extending laterally from the side wall of the back dorsal portion which defines an extended internal space, the resiliently deformable flange has inner and outer surfaces that extend to a circumferential edge.

A device (100) for facilitating the positioning of a catheter for the administration of a liquid medicament to a spontaneously breathing patient. The method and system according to preferred embodiments of the present invention allows optimizing the dispensing said medicaments. In particular the system according to a preferred embodiment of the present invention allows the administration of an exogenous pulmonary surfactant to preterm patients.

Techniques for blockage removal are provided, which may provide immediate and effective aid to a choking victim. A blockage removal device may comprise a mouthpiece disposed on an inlet. The inlet may be coupled to a chamber configured to hold a vacuum generated by a vacuum pump. A vacuum gauge may display information to a user, who may open or close a valve to provide or remove a vacuum to attempt to remove a blockage.

Compounds and methods for preventing or treating upper respiratory virus infections in humans and animal species are disclosed. The compounds may exhibit antimicrobial, antiviral, anti-inflammatory, anticoagulant or cytoprotective activities. The methods may deliver compounds to be delivered to the nasal and oral cavities, nasopharynx, and posterior pharynx, the primary sites of upper respiratory infections, such as influenza, SARS, and SARS-CoV-2. Therapeutic swabs comprising one or more compounds are may be used to deliver one or more compounds to deliver the above primary sites of the individuals infected with one or more upper respiratory viruses or other pathogens.

Disclosed herein are devices and methods for improved transnasal and transoral nasopharyngeal diagnostics and therapeutics, particularly to detect the presence of infectious agents such as a coronavirus, for example SARS-CoV-2, responsible for COVID-19, and other viral agents.

A handheld therapeutic apparatus and method of treatment are disclosed. In one example, the apparatus includes a valve system, a detachable gas cartridge housing unit that houses a gas cartridge or gas delivery from an outside gas cylinder in fluid communication with said valve system, a detachable treatment receptacle for the delivery of gas therapies is in fluid communication with said valve system, and a detachable nozzle in fluid communication with said valve system.

The improvement device provides an oral suction system for use with endo-tracheal tubes. The device provides alternative anti-infective components and a removable and/or disposable external sleeve, both for mitigation or elimination of risks for viral and/or bacterial contamination of the patient and healthcare professional.

The present disclosure relates to a system and a method for automatically measuring and assessing hemodynamics in tissue of an anatomical structure of a subject. In particular the present disclosure relates to continuously measuring and assessing hemodynamics in medical procedures using fluorescence imaging and wherein the administration of the fluorescent agent is controlled and automated. One aspect relates to a method of automatic perfusion assessment of an anatomical structure of a subject, the method comprising administration into a vein of a bolus corresponding to less than 0.005 mg ICG/kg body weight of a first fluorescence imaging agent. Another aspect relates to a system for automatic perfusion assessment of an anatomical structure during a medical procedure of a subject comprising a controllable injection pump for holding at least one first fluorescence imaging agent, the injection pump being configured for injecting a predefined amount of said first fluorescence imaging agent into the blood of the subject, wherein the system is configured for receiving and analysing a time series of fluorescence images of the tissue of said anatomical structure following the injection of the first fluorescence imaging agent, and determining at least one perfusion parameter of said anatomical structure based on said analysis.

Embodiments generally relate to a device for monitoring air pressure in the body of a patient. The device comprises a tube comprising a feeding lumen; a sensor lumen positioned parallel to the feeding lumen; at least one sensor positioned in the sensor lumen; and at least one perforation positioned to expose the at least one sensor to an air pressure within the body of a patient when the device is positioned at least partially in the airway of the patient. The at least one sensor is configured to generate data related to the pressure to which the sensor has been exposed.

Compounds and methods for preventing or treating upper respiratory virus infections in humans and animal species are disclosed. The compounds may exhibit antimicrobial, antiviral, anti-inflammatory, anticoagulant or cytoprotective activities. The methods may deliver compounds to be delivered to the nasal and oral cavities, nasopharynx, and posterior pharynx, the primary sites of upper respiratory infections, such as influenza, SARS, and SARS-CoV-2. Therapeutic swabs comprising one or more compounds are may be used to deliver one or more compounds to deliver the above primary sites of the individuals infected with one or more upper respiratory viruses or other pathogens.